Figure 6.

miR-380 targets and regulates FGF9. A-B, mRNA microarray was performed based on 4 spinal cord tissues of SCI and sham-operated rats for volcano plot (a) and heatmap (b) mapping; C, Venn diagram showing the number of miRNAs with binding relationship predicted by algorithms StarBase, TargetScan, miRDB and differentially expressed miRNAs in GSE450006 microarray; D-E, expression of FGF9 mRNA (d) and protein (e) in rat spinal cord tissues by RT-qPCR and western blot (n = 6); F-G, expression of FGF9 mRNA (f) and protein (g) in PC12 cells detected by RT-qPCR and western blot; H, binding sites of miR-380 to FGF9; I, dual-luciferase assay determination of the binding relationship between miR-380 and FGF9; J, biotin-labeled RNA pull-down assay detection of the binding relationship between miR-380 and FGF9. Data were presented as the mean ± SD. All experiments were repeated at least three times, and each experiment was performed in triplicate. One-way (panels D-G and J) or two-way ANOVA (panel I) with Tukey’s post-hoc test was used for statistical analysis. **p < 0.01 vs sham-operated rats, mimic NC or Oligo/miR-380-mt treatment; ##p < 0.01 vs SCI rats injected with Lv-NC; &&p < 0.01 vs PC12 cells treated with normal condition; @@p < 0.01 vs PC12 cells transfected with Lv-NC and exposed to OGD; $$p < 0.01 vs PC12 cells transfected with Lv-circTYW1 + NC and exposed to OGD; %%p < 0.01 vs PC12 cells transfected with Lv-shcircTYW1 + inhibitor NC and exposed to OGD